Sol-Gel Technologies (SLGL) Income towards Parent Company (2017 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Income towards Parent Company came in at $3.7 million in Q1 2026, down 57.69% year-on-year from $8.8 million in Q1 2025, and up 106.02% on a QoQ basis from -$61.9 million in Q4 2025.
Sol-Gel Technologies (SLGL) Income towards Parent Company (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 10 years of Income towards Parent Company data on file, last reported at $3.7 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 57.69% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was -$53.2 million, a 15.04% decrease from a year earlier, with the FY2025 full-year figure at -$66.0 million, down 6.86% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $3.7 million, up from -$61.9 million in the prior quarter.
- Over the last five years, Income towards Parent Company for SLGL reached as high as $11.2 million in Q2 2025 and fell as low as -$61.9 million in Q4 2025.
- Historically, Income towards Parent Company has averaged -$10.8 million across 5 years, with a median of $134000.0 in 2022.
- Across the five-year window, Income towards Parent Company surged 4355.22% in 2023 and tumbled 659.42% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$50.9 million in 2022, then slipped by 4.75% to -$53.3 million in 2023, then retreated by 4.82% to -$55.9 million in 2024, then decreased by 10.78% to -$61.9 million in 2025, then jumped by 106.02% to $3.7 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were $3.7 million in Q1 2026, -$61.9 million in Q4 2025, and -$6.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Sol-Gel Technologies | 234.04 Mn | 223.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.73 Mn |
| Dec 31, 2025 | -61.92 Mn |
| Sep 30, 2025 | -6.29 Mn |
| Jun 30, 2025 | 11.23 Mn |
| Mar 31, 2025 | 8.81 Mn |
| Dec 31, 2024 | -55.89 Mn |
| Sep 30, 2024 | -828,000.00 |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 6.34 Mn |
| Dec 31, 2023 | -53.32 Mn |
| Sep 30, 2023 | -5.71 Mn |
| Jun 30, 2023 | 5.97 Mn |
| Mar 31, 2023 | 10.72 Mn |
| Dec 31, 2022 | -50.90 Mn |
| Sep 30, 2022 | -3.41 Mn |
| Jun 30, 2022 | 134,000.00 |
| Mar 31, 2022 | 5.60 Mn |
| Dec 31, 2021 | 13.55 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 8.03 Mn |